Results 21 to 30 of about 57,324 (252)
Aging impairs CD8 T cell responses in adoptive T-cell therapy against solid tumors. [PDF]
Front ImmunolKadyrzhanova G +4 more
europepmc +2 more sources
Adoptive T‐cell therapy for cancer: The era of engineered T cells [PDF]
European Journal of Immunology, 2015 Tumors originate from a number of genetic events that deregulate homeostatic mechanisms controlling normal cell behavior. The immune system, devoted to patrol the organism against pathogenic events, can identify transformed cells, and in several cases cause their elimination.
BONINI , MARIA CHIARA, Mondino A.
openaire +3 more sources
Adoptive T cell therapy: Addressing challenges in cancer immunotherapy
Journal of Translational Medicine, 2005 Adoptive T cell therapy involves the ex vivo selection and expansion of effector cells for the treatment of patients with cancer. In this review, the advantages and limitations of using antigen-specific T cells are discussed in counterpoint to vaccine ...
Yee Cassian
doaj +1 more source
Frontiers in Oncology, 2022 Peripheral T-cell lymphoma (PTCL) is a type of highly heterogeneous non-Hodgkin lymphoma with a poor prognosis and lack of effective targeted therapies. Adoptive T-cell therapy has been successfully used in the treatment of B-cell malignancies.
Yuan Chen +6 more
doaj +1 more source
Synthetic Antigen‐Presenting Cells for Adoptive T Cell Therapy [PDF]
Advanced Therapeutics, 2021 Abstract Adoptive T cell therapies are transforming the treatment of solid and liquid tumors, yet their widespread adoption is limited in part by the challenge of generating functional cells. T cell activation and expansion using conventional antigen‐presenting cells (APCs) is unreliable due to the variable quality of donor‐derived ...
Shreyas N. Dahotre +3 more
openaire +2 more sources
Frontiers in Immunology, 2019 The successful generation of T cell-mediated immunity for the treatment of cancer has been a major focal point of research. One of the critical strategies of cancer immunotherapy is to efficiently activate antigen-specific CD8 T cells in the ...
Jin-Zhi Lai +5 more
doaj +1 more source
Frontiers in Immunology, 2023 Recurrent neoepitopes are cancer-specific antigens common among groups of patients and therefore ideal targets for adoptive T cell therapy. The neoepitope FSGEYIPTV carries the Rac1P29S amino acid change caused by a c.85C>T missense mutation, which is
Lena Immisch +15 more
doaj +1 more source
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer
Journal of Translational Medicine, 2012 A summit on cellular therapy for cancer discussed and presented advances related to the use of adoptive cellular therapy for melanoma and other cancers. The summit revealed that this field is advancing rapidly.
Stroncek David F +17 more
doaj +1 more source
Adoptive T-Cell Therapy for Solid Tumors [PDF]
American Society of Clinical Oncology Educational Book, 2017 Chimeric antigen receptor (CAR) T-cell therapy is an innovative form of immunotherapy wherein autologous T cells are genetically modified to express chimeric receptors encoding an antigen-specific single-chain variable fragment and various costimulatory molecules. Upon administration, these modified T cells traffic to, and recognize, cancer cells in an
Oladapo, Yeku +2 more
openaire +2 more sources
Harnessing Autophagy for Adoptive T-Cell Therapy [PDF]
Immunotherapy, 2011 Allogeneic hematopoietic cell transplantation (HCT), which is a treatment option for leukemia and lymphoma (reviewed in[1]), represents a form of adoptive T cell therapy (the graft-versus-tumor [GVT] effect). The majority of allogeneic transplants are performed using un-manipulated donor T cells, although as we will describe below, ex vivo manipulated ...
Shoba, Amarnath, Daniel H, Fowler
openaire +2 more sources